These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
225 related articles for article (PubMed ID: 25913250)
21. Long-lasting immunogenicity of a virosomal vaccine in older children and young adults with type I diabetes mellitus. Zuccotti GV; Scaramuzza A; Riboni S; Mameli C; Pariani E; Tanzi E; Zanetti A; Radaelli G Vaccine; 2009 Aug; 27(39):5357-62. PubMed ID: 19607951 [TBL] [Abstract][Full Text] [Related]
22. Shedding of Ann Arbor strain live attenuated influenza vaccine virus in children 6-59 months of age. Mallory RM; Yi T; Ambrose CS Vaccine; 2011 Jun; 29(26):4322-7. PubMed ID: 21513761 [TBL] [Abstract][Full Text] [Related]
23. Comparison between a conventional subunit vaccine and the MF59-adjuvanted subunit influenza vaccine in the elderly: an evaluation of the safety, tolerability and immunogenicity. Sindoni D; La Fauci V; Squeri R; Cannavò G; Bacilieri S; Panatto D; Gasparini R; Amicizia D J Prev Med Hyg; 2009 Jun; 50(2):121-6. PubMed ID: 20099444 [TBL] [Abstract][Full Text] [Related]
24. Enhanced Stability of Inactivated Influenza Vaccine Encapsulated in Dissolving Microneedle Patches. Chu LY; Ye L; Dong K; Compans RW; Yang C; Prausnitz MR Pharm Res; 2016 Apr; 33(4):868-78. PubMed ID: 26620313 [TBL] [Abstract][Full Text] [Related]
25. Using surveillance to evaluate influenza vaccine effectiveness. Jackson LA J Infect Dis; 2009 Jan; 199(2):155-8. PubMed ID: 19086916 [No Abstract] [Full Text] [Related]
26. Immunogenicity and reactogenicity of 1 versus 2 doses of trivalent inactivated influenza vaccine in vaccine-naive 5-8-year-old children. Neuzil KM; Jackson LA; Nelson J; Klimov A; Cox N; Bridges CB; Dunn J; DeStefano F; Shay D J Infect Dis; 2006 Oct; 194(8):1032-9. PubMed ID: 16991077 [TBL] [Abstract][Full Text] [Related]
27. Improved antibody responses in infants less than 1 year old using intradermal influenza vaccination. Sugimura T; Ito Y; Tananari Y; Ozaki Y; Maeno Y; Yamaoka T; Kudo Y Vaccine; 2008 May; 26(22):2700-5. PubMed ID: 18436353 [TBL] [Abstract][Full Text] [Related]
28. Antibody responses to trivalent influenza vaccine in Iranian adults infected with human immunodeficiency virus. Rasoolinejad M; Jafari S; Montazeri M; Mohseni M; Foroughi M; Moradmand Badie B; Saatian M; Marashi SM; Mokhtari Azad T Acta Med Iran; 2013 Apr; 51(3):148-52. PubMed ID: 23605597 [TBL] [Abstract][Full Text] [Related]
29. Serum antibody responses after intradermal vaccination against influenza. Belshe RB; Newman FK; Cannon J; Duane C; Treanor J; Van Hoecke C; Howe BJ; Dubin G N Engl J Med; 2004 Nov; 351(22):2286-94. PubMed ID: 15525713 [TBL] [Abstract][Full Text] [Related]
30. Vaccination of an adolescent group with A (H3N2) + A(HSW1N1) bivaccine before an A (H1N1) influenza epidemic. Stumpa A; Cihla F; Tůmová B; Husek V; Slezácek J Acta Virol; 1979 Sep; 23(5):443-5. PubMed ID: 42307 [TBL] [Abstract][Full Text] [Related]
31. Safety and immunogenicity of a trivalent single dose seasonal influenza vaccine containing pandemic A(H1N1) antigen in younger and elderly subjects: a phase III open-label single-arm study. Loebermann M; Anders G; Brestrich G; Fritzsche C; Klammt S; Boršo D; Frimmel S; Riebold D; Reisinger EC Vaccine; 2011 Feb; 29(6):1228-34. PubMed ID: 21167116 [TBL] [Abstract][Full Text] [Related]
32. Generation and evaluation of the trivalent inactivated reassortant vaccine using human, avian, and swine influenza A viruses. Du N; Li W; Li Y; Liu S; Sui Y; Qu Z; Wang Y; Du Y; Xu B Vaccine; 2008 Jun; 26(23):2912-8. PubMed ID: 18448208 [TBL] [Abstract][Full Text] [Related]
33. Formulation Approach that Enables the Coating of a Stable Influenza Vaccine on a Transdermal Microneedle Patch. Ameri M; Ao Y; Lewis H AAPS PharmSciTech; 2021 Jun; 22(5):175. PubMed ID: 34114100 [TBL] [Abstract][Full Text] [Related]
34. Pre-vaccination immunity and immune responses to a cell culture-derived whole-virus H1N1 vaccine are similar to a seasonal influenza vaccine. Ehrlich HJ; Müller M; Kollaritsch H; Pinl F; Schmitt B; Zeitlinger M; Loew-Baselli A; Kreil TR; Kistner O; Portsmouth D; Fritsch S; Maritsch F; Aichinger G; Pavlova BG; Barrett PN Vaccine; 2012 Jun; 30(30):4543-51. PubMed ID: 22475864 [TBL] [Abstract][Full Text] [Related]
36. Evaluation of the safety, reactogenicity and immunogenicity of FluBlok® trivalent recombinant baculovirus-expressed hemagglutinin influenza vaccine administered intramuscularly to healthy adults 50-64 years of age. Baxter R; Patriarca PA; Ensor K; Izikson R; Goldenthal KL; Cox MM Vaccine; 2011 Mar; 29(12):2272-8. PubMed ID: 21277410 [TBL] [Abstract][Full Text] [Related]
37. Phase I/II trial of a replication-deficient trivalent influenza virus vaccine lacking NS1. Mössler C; Groiss F; Wolzt M; Wolschek M; Seipelt J; Muster T Vaccine; 2013 Dec; 31(52):6194-200. PubMed ID: 24183981 [TBL] [Abstract][Full Text] [Related]
38. Safety, tolerability, and immunogenicity of inactivated trivalent seasonal influenza vaccine administered with a needle-free disposable-syringe jet injector. Simon JK; Carter M; Pasetti MF; Sztein MB; Kotloff KL; Weniger BG; Campbell JD; Levine MM Vaccine; 2011 Nov; 29(51):9544-50. PubMed ID: 21986218 [TBL] [Abstract][Full Text] [Related]